Pathstone Holdings’s Bristol-Myers Squibb BMY Stock Holding History

Pathstone Holdings’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.8M	Buy	226,925 +41,072	+22%	+$2.39M	0.05%	243
2025 Q4	$10M	Sell	185,853 -22,578	-11%	-$1.09M	0.04%	339
2025 Q3	$9.4M	Sell	208,431 -38,856	-16%	-$1.81M	0.04%	355
2025 Q2	$11.4M	Buy	247,287 +30,634	+14%	+$1.5M	0.05%	286
2025 Q1	$13.2M	Buy	216,653 +5,786	+3%	+$337K	0.06%	249
2024 Q4	$11.9M	Buy	210,867 +21,917	+12%	+$1.22M	0.05%	250
2024 Q3	$9.78M	Buy	188,950 +4,062	+2%	+$191K	0.04%	328
2024 Q2	$7.68M	Sell	184,888 -28,081	-13%	-$1.26M	0.03%	389
2024 Q1	$11.5M	Sell	212,969 -11,765	-5%	-$599K	0.05%	266
2023 Q4	$11.6M	Buy	+224,734	New	+$11.8M	0.06%	235

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pathstone Holdings's BMY Position: Q1 2026 in Review

Pathstone Holdings increased its Bristol-Myers Squibb (BMY) stake by 22% in Q1 2026, buying an estimated $2.39M and bringing the position to 226,925 shares worth $13.8M. The position accounts for 0.05% of the portfolio, ranked #243.

Pathstone Holdings first reported a position in BMY in Q4 2023 and has held it in 10 quarters since. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Pathstone Holdings held 226,925 shares of Bristol-Myers Squibb worth $13.8M as of Q1 2026.
Pathstone Holdings bought 41,072 Bristol-Myers Squibb shares in Q1 2026, an estimated $2.39M.
Bristol-Myers Squibb made up 0.05% of Pathstone Holdings's portfolio in Q1 2026, its #243 holding.
Pathstone Holdings first reported a position in Bristol-Myers Squibb in Q4 2023 and has held it in 10 quarters since.
2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Pathstone Holdings's 13F filing for Q1 2026, filed 11 May 2026.